IBS & irritable bowel — all decisions

The Board remands the claims for service connection for irritable bowel syndrome and gastroesophageal reflux disease to the AOJ for further development, including obtaining a VA examination.

The Board granted service connection for irritable bowel syndrome and assigned initial ratings of 30 percent for migraines, 20 percent for each ankle condition, and 40 percent for lumbar strain. Effective dates earlier than July 7, 2022, were denied for the ankle, migraine, and lumbar strain conditions, while an effective date of August 17, 2022, was granted for sinusitis.

The Board granted an effective date of December 17, 2018, for the award of service connection for other specified trauma disorder and stressor related disorder. Other claims were denied or remanded.

The Board remands the claim for service connection of irritable bowel syndrome (IBS) to obtain a clarifying medical opinion regarding its potential relationship with the Veteran's service-connected major depressive disorder.

The Board denied the claims for earlier effective dates and remanded several service connection claims.

The Board granted an initial rating of 10 percent for irritable bowel syndrome (IBS) with chronic diarrhea.

The Board denied service connection for irritable bowel syndrome as there is no evidence of a current diagnosis and the condition is not etiologically related to service.

The Board denied service connection for irritable bowel syndrome, chronic fatigue syndrome, and left knee disability as the evidence did not support a finding that these conditions began during active service or are otherwise related to an in-service injury or disease.

The Board denied the veteran's claims for increased ratings and service connection, as well as remanded certain claims for further development.

The Board granted earlier effective dates for the service connection of various conditions related to lung cancer, including scars, pain, and hearing loss, but denied an earlier effective date for non-small cell lung cancer itself.

The Veteran was granted a 30 percent rating for GERD, effective September 15, 2020, but the claim for a higher rating for IBS with GERD from October 4, 2022, was denied.

The Board granted service connection for various conditions, including obstructive sleep apnea, left hip condition, GERD, irritable bowel syndrome, back condition, right knee condition, left ankle condition, right ankle condition, erectile dysfunction, and bilateral lower extremity radiculopathy, all secondary to the Veteran's service-connected bilateral foot/toe conditions.

The Board granted a 30 percent rating for the Veteran's stress fracture, mid-distal femur, right leg with limited flexion and restored the 30 percent rating for the Veteran's stress fracture, mid-distal femur, right leg with limitation of abduction and rotation. The other claims were denied.

The Board remands the claims for irritable bowel syndrome and insomnia, also claimed as chronic fatigue syndrome, to correct predecisional duty to assist errors.

The appeal for issues related to eczema, IBS, headaches, liver disability, enlarged prostate and urinary frequency, allergic rhinitis, and restrictive lung disease were dismissed. The claim for a rating in excess of 10 percent for allergic rhinitis was denied.

The Veteran's appeal requests for the specified rating decisions were denied as they were not timely filed, and good cause was not shown to accept late filings.

The Board remands the claims for service connection for flat feet, irritable bowel syndrome, duodenal gastritis, and fecal incontinence to correct pre-decisional duty to assist errors.

The Board granted service connection for irritable bowel syndrome (IBS) as secondary to the Veteran's service-connected moderate recurrent major depressive disorder with anxious distress.

The Board granted a 40 percent rating for the Veteran's left shoulder disability and a 30 percent rating for the right shoulder disability, effective October 19, 2023.

The Board denied the veteran's claims for increased ratings for PTSD, dermatitis, and IBS, finding that the evidence did not support a higher rating.